company mission and NAD+ longevity theory
Nuchido's core belief barely moved across these three snapshots. In 2020 it already framed NAD+ as a central lever in ageing, describing higher cellular NAD+ as one of the best ways to combat ageing and tying it to healthspan, independence, and even innate immune defence against viral infection. By 2021 and 2022, that same NAD+ longevity theory stayed in place: ageing is at least partly addressable through science, and maintaining or restoring NAD+ supports cellular health, repair, energy, and performance. What changed was the mission language around that theory. The 2020 version is more direct and mechanistic: boost NAD+, support healthy ageing. In 2021 the company adds a broader philosophical layer about purpose, responsibility, and helping people live out their vision for life. By 2022 that framing gets more branded and self-descriptive, with Nuchido presenting itself as a mission-driven collective of scientists, doctors, futurists, and impact-minded operators, while also pushing its proprietary whole-system supplement approach more explicitly. So the belief evolution is mostly a packaging shift, not a scientific reversal. The company moves from a fairly blunt NAD+ and ageing claim to a fuller identity story plus stronger product positioning, but the underlying thesis stays stable. Evidence is thin on whether its confidence in NAD+ changed in response to new data, because these snapshots show homepage messaging, not internal research updates or a clear before-and-after scientific argument.